Sept 28, 2023

Our collaboration with Teresa R. O'Meara at the University of Michigan has culminated in an article published in #Science. In this groundbreaking work, we discovered a new surface adhesin protein, SCF1, on the multi-drug-resistant pathogen Candida auris. This protein plays a crucial role in biofilm formation, skin colonization, and virulence during systemic infections. Given the high mortality rate and drug resistance associated with Candida auris infection, this study carries significant clinical implications. It paves the way for the development of alternative immune-based therapies targeting the SCF1 surface protein. It's worth mentioning that both the #CDC and #WHO have already declared #Candidaauris a "Serious Threat Level" #pathogen

Read full story here:

Jan 12, 2023

Developing alternative immunotherapies against multi-drug resistant Candida auris, a "serious health threat level pathogen", is the key to controlling this fungus. For more, read our new article in Journal of Fungi.


July 22, 2022

Pre-term infants in neonatal intensive care units (NICU) are at high risk of fungal sepsis. In this population, Candida albicans remains the predominant fungal pathogen causing high morbidity and mortality, despite antifungal therapy. Dr. Uppuluri's Lab in collaboration with Singh HITS Lab shows that immunotherapeutic strategies including vaccinating mothers or antibody treatment of infants could have huge protective benefits in this population. Read the full story published in Frontiers in Immunology

July 18, 2022

Dr. Singh got UCLA CTSI KL2 Translational Science Award 2022 for three years.

March 17, 2022

Dr. Singh got an American Heart Association Grant for three years.